000 01381 a2200409 4500
005 20250515192128.0
264 0 _c20110411
008 201104s 0 0 eng d
022 _a1573-0646
024 7 _a10.1007/s10637-009-9346-1
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aDiaz, Luis A
245 0 0 _aTNF-blockade in patients with advanced hormone refractory prostate cancer.
_h[electronic resource]
260 _bInvestigational new drugs
_cFeb 2011
300 _a192-4 p.
_bdigital
500 _aPublication Type: Clinical Trial; Journal Article
650 0 4 _aAged
650 0 4 _aAntibodies, Monoclonal
_xpharmacology
650 0 4 _aDrug Resistance, Neoplasm
_xdrug effects
650 0 4 _aHumans
650 0 4 _aInfliximab
650 0 4 _aInterleukin-6
_xmetabolism
650 0 4 _aMale
650 0 4 _aMiddle Aged
650 0 4 _aNeoplasm Staging
650 0 4 _aProstatic Neoplasms
_xdrug therapy
650 0 4 _aTreatment Outcome
650 0 4 _aTumor Necrosis Factor-alpha
_xantagonists & inhibitors
700 1 _aMessersmith, Wells
700 1 _aSokoll, Lori
700 1 _aSinibaldi, Vicki
700 1 _aMoore, Sandy
700 1 _aCarducci, Michael
700 1 _aEisenberger, Mario
773 0 _tInvestigational new drugs
_gvol. 29
_gno. 1
_gp. 192-4
856 4 0 _uhttps://doi.org/10.1007/s10637-009-9346-1
_zAvailable from publisher's website
999 _c19236314
_d19236314